Role of eicosanoids in pathogenic human CoV infections
Role of eicosanoids in pathogenic human CoV infections
批准号:
9542722
负责人:
Stanley Perlman
金额:
$54.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-23 至 2021-08-31
关键词:
AffectAgeAge-YearsAgingAlveolar MacrophagesAnti-inflammatoryAntigensCase Fatality RatesCellsCellular MembraneChronicCoronavirusCoronavirus InfectionsDataDendritic CellsDendritic cell activationDependenceDepressed moodDinoprostoneDiseaseDopamine D2 ReceptorEicosanoidsElderlyExposure toFundingGeneticGoalsHumanITGAX geneImmune responseIndividualInfectionInflammasomeInflammationInflammatoryInterferonsKnock-in MouseKnock-outLungLung diseasesMediatingMiddle East Respiratory Syndrome CoronavirusMusMyeloid Cell ActivationMyeloid CellsOutcomeOxidative Stress InductionOxidesPathogenesisPathogenicityPathway interactionsPatientsPhospholipasePhospholipase A2PhospholipidsPropertyProstaglandin D2ProstaglandinsRespiratory Tract InfectionsRoleSevere Acute Respiratory SyndromeSeveritiesSeverity of illnessSignal TransductionT cell responseUp-RegulationVaccinesViralVirulentVirusage relatedagedaging populationbasecell motilitylipid mediatorlymph nodesmembermiddle agemortalitynew therapeutic targetpathogenreceptorrespiratoryresponsevaccine response
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) are
coronavirus-mediated human respiratory diseases with high case-fatality rates. Disease is especially severe in
aged populations. In the previous funding period, we showed that age-dependent increases in prostaglandin
D2 (PGD2) and an upstream phospholipase A2, PLA2G2D contributed to poor immune responses and
decreased survival. The lung is in a state of chronic inflammation, resulting from continued exposure to
environmental antigens. We postulated that PLA2G2D, which has anti-inflammatory properties, is upregulated
to counter this low grade inflammation, resulting in delayed responses to innocuous antigens but also to rapidly
replicating viruses like MERS-CoV and SARS-CoV. Transient blockade of PGD2 signaling or genetic absence
of PLA2G2D greatly increased survival. In marked contrast, “knock-out” of DP1, the PGD2 receptor on myeloid
cells, converted a sublethal SARS-CoV infection to a lethal one, indicating that PGD2/DP1 signaling has
additonal roles in the infected lung. Our central hypothesis is that PGD2 and PLA2G2D along with other
members of the small lipid mediator pathways have central roles in modulating the inflammatory state of the
lung. In specific, they regulate multiple steps in the innate and subsequent T cell responses in mice infected
with SARS-CoV, MERS-CoV and likely other viral respiratory pathogens. This hypothesis will be approached
in the following specific aims: 1. To determine the mechanism of PLA2G2D upregulation and the role of
PLA2G2D in vaccine responses in 12m old mice. CoV replication includes extensive cellular membrane
rearrangements. The role between these rearrangements, the induction of oxidative stress and the
upregulation of PLA2G2D will be investigated. 2. To determine the role of PGD2-DP1 signaling in the immune
response to SARS-CoV in 12 m mice. The absence of PGD2-DP1 signaling results in diminished rDC
activation and type I IFN (IFN-I) expression and increased inflammasome activation. Our goal is to determine
whether changes in inflammasome activation are the major pathogenic effect of absent PGD2-DP1 signaling or
if other factors are also involved. 3. To determine whether PGD2 and PLA2G2D contribute to poorer outcomes
in mice infected with MERS-CoV, another infection in which severity is age-dependent. Using our newly
developed hDPP4-KI mice and mouse-adapted MERS-CoV, we will determine whether MERS-CoV in mice
also causes an age-dependent disease and whether changes in eicosanoid expression contribute to more
severe disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of eicosanoids in pathogenic human CoV infections
-
批准号:9764251
-
项目类别:
-
资助金额:$54.52万
-
财政年份:2016
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8847630
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Animal Core
-
批准号:8055144
-
项目类别:
-
资助金额:$22.62万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8164278
-
项目类别:
-
资助金额:$37.73万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8264955
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8055138
-
项目类别:
-
资助金额:$31.54万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8468102
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Administrative Core
-
批准号:8055145
-
项目类别:
-
资助金额:$13.24万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8663180
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
A novel strategy for developing a SARS-CoV vaccine
-
批准号:7904591
-
项目类别:
-
资助金额:$40.33万
-
财政年份:2009
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:8304203
-
项目类别:
-
资助金额:$159.58万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:8021280
-
项目类别:
-
资助金额:$159.97万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: HOST VIRUS INTERACTIONS IN HCoV-SARS INFECTIONS
-
批准号:7120540
-
项目类别:
-
资助金额:$144.54万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:9752412
-
项目类别:
-
资助金额:$125.43万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:8881046
-
项目类别:
-
资助金额:$159.58万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
Project 1
-
批准号:10229390
-
项目类别:
-
资助金额:$8.0万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:8494515
-
项目类别:
-
资助金额:$160.57万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
Project 4
-
批准号:9209901
-
项目类别:
-
资助金额:$19.54万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
Development of Murine Model for SARS-CoV Pathogenesis
-
批准号:6825517
-
项目类别:
-
资助金额:$28.54万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
Project-004
-
批准号:10229091
-
项目类别:
-
资助金额:$18.24万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: